Knocking down cyclin D1b inhibits breast cancer cell growth and suppresses tumor development in a breast cancer model

Cancer Science

Volumn 102, Issue 8, 2011, Pages 1537-1544

  Wei, Min ^a   Zhu, Li ^b   Li, Yafen ^b   Chen, Weiguo ^b   Han, Baosan ^b   Wang, Zhiwei ^a   He, Jianrong ^b   Yao, Hongliang ^c   Yang, Zhongyin ^a   Zhang, Qing ^a   Liu, Bingya ^a   Gu, Qinlong ^a   Zhu, Zhenggang ^a   Shen, Kunwei ^b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN D1B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER MODEL; CARCINOGENESIS; CELL GROWTH; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DOXORUBICIN; FEMALE; G1 PHASE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; PROTEIN ISOFORMS; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960425056     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01969.x     Document Type: Article

References (59)

1. Arnold A, Motokura T, Bloom T et al. PRAD1 (cyclin D1): a parathyroid neoplasia gene on 11q13. Henry Ford Hosp Med J 1992; 40: 177-80.
2. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 1992; 52: 2980-3.
3. Por E, Byun HJ, Lee EJ et al. The cancer/testis antigen CAGE with oncogenic potential stimulates cell proliferation by up-regulating cyclins D1 and E in an AP-1- and E2F-dependent manner. J Biol Chem 2010; 285: 14475-85.
4. Scime A, Li L, Ciavarra G, Whyte P. Cyclin D1/cdk4 can interact with E2F4/DP1 and disrupts its DNA-binding capacity. J Cell Physiol 2008; 214: 568-81.
5. Kobayashi S, Shimamura T, Monti S et al. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res 2006; 66: 11.
6. Zhong Z, Yeow WS, Zou C et al. Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells. Cancer Res 2010; 70: 2105-14.
7. Molenaar JJ, Ebus ME, Koster J et al. Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res 2008; 68: 2599-609.
8. Takahashi-Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal 2008; 20: 581-9.
9. Pontano LL, Diehl JA. Speeding through cell cycle roadblocks: nuclear cyclin D1-dependent kinase and neoplastic transformation. Cell Div 2008; 3: 12.
10. Boukamp P, Popp S, Bleuel K, Tomakidi E, Burkle A, Fusenig NE. Tumorigenic conversion of immortal human skin keratinocytes (HaCaT) by elevated temperature. Oncogene 1999; 18: 5638-45.
11. Knudsen KE. The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Div 2006; 1: 15.
12. Oswald F, Lovec H, Moroy T, Lipp M. E2F-dependent regulation of human MYC: trans-activation by cyclins D1 and A overrides tumour suppressor protein functions. Oncogene 1994; 9: 2029-36.
13. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 2006; 25: 1620-8.
14. Sanchez G, Bittencourt D, Laud K et al. Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer. Proc Natl Acad Sci USA 2008; 105: 6004-9.
15. Burd CJ, Petre CE, Morey LM et al. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci USA 2006; 103: 2190-5.
16. Millar EK, Dean JL, McNeil CM et al. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene 2009; 28: 1812-20.
17. Wang Y, Dean JL, Millar EK et al. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res 2008; 68: 5628-38.
18. Daher A, Laraki G, Singh M et al. TRBP control of PACT-induced phosphorylation of protein kinase R is reversed by stress. Mol Cell Biol 2009; 29: 254-65.
19. Lee Y, Hur I, Park SY, Kim YK, Suh MR, Kim VN. The role of PACT in the RNA silencing pathway. EMBO J 2006; 25: 522-32.
20. Kok KH, Ng MH, Ching YP, Jin DY. Human TRBP and PACT directly interact with each other and associate with dicer to facilitate the production of small interfering RNA. J Biol Chem 2007; 282: 17.
21. Skordis LA, Dunckley MG, Yue B, Eperon IC, Muntoni F. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci USA 2003; 100: 4114-9.
22. Love KT, Mahon KP, Levins CG et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 2010; 107: 1864-9.
23. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009; 8: 129-38.
24. Akinc A, Goldberg M, Qin J et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther 2009; 17: 872-9.
25. Novina CD, Sharp PA. The RNAi revolution. Nature 2004; 430: 161-4.
26. Sasaki T, Nakashiro K, Tanaka H et al. Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo. Biochem Biophys Res Commun 2010; 399: 79-83.
27. Ma YP, Yang Y, Zhang S et al. Efficient inhibition of lung cancer in murine model by plasmid-encoding VEGF short hairpin RNA in combination with low-dose DDP. J Exp Clin Cancer Res 2010; 29: 56.
28. Fuessel S, Meye A, Kraemer K, Kunze D, Hakenberg OW, Wirth MP. Synthetic nucleic acids as potential therapeutic tools for treatment of bladder carcinoma. Eur Urol 2007; 51: 315-26.
29. Alexopoulou AN, Leao M, Caballero OL et al. Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines. Breast Cancer Res 2010; 12: R51.
30. Wei M, Liu B, Su L et al. A novel plant homeodomain finger 10-mediated antiapoptotic mechanism involving repression of caspase-3 in gastric cancer cells. Mol Cancer Ther 2010; 9: 1764-74.
31. Wang YW, Qu Y, Li JF et al. In vitro and in vivo evidence of metallopanstimulin-1 in gastric cancer progression and tumorigenicity. Clin Cancer Res 2006; 12: 4965-73.
32. Qu Y, Li JF, Cai Q et al. Over-expression of FRZB in gastric cancer cell suppresses proliferation and induces differentiation. J Cancer Res Clin Oncol 2008; 134: 353-64.
33. Zhao TT, Trinh D, Addison CL, Dimitroulakos J. Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitors. PLoS ONE 2010; 5: e12563.
34. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-6.
35. Chou TC. Preclinical versus clinical drug combination studies. Leuk Lymphoma 2008; 49: 2059-80.
36. Carbone PP. Chemotherapy in the treatment strategy of breast cancer. Cancer 1975; 36: 633-7.
37. Tabchy A, Valero V, Vidaurre T et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 2010; 16: 5351-61.
38. Jeselsohn R, Brown NE, Arendt L et al. Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis. Cancer Cell 2010; 17: 65-76.
39. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-6.
40. Lamb J, Ramaswamy S, Ford HL et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 2003; 114: 323-34.
41. Li Z, Jiao X, Wang C et al. Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res 2010; 70: 8802-11.
42. Abramson VG, Troxel AB, Feldman M et al. cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome. Anticancer Res 2010; 30: 1279-85.
43. Bostrom P, Soderstrom M, Palokangas T et al. Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors. BMC Res Notes 2009; 2: 140.
44. Liu B, Fan Z, Edgerton SM et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009; 8: 2031-40.
45. Kalashnikova EV, Revenko AS, Gemo AT et al. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of b-myb and EZH2. Cancer Res 2010; doi: 10.1158/0008-5472.CAN-10-1199 [Epub ahead of print].
46. Rahman M, Davis SR, Pumphrey JG et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 2009; 113: 217-30.
47. Spadari S, Pedrali-Noy G, Focher F et al. DNA polymerases and DNA topoisomerases as targets for the development of anticancer drugs. Anticancer Res 1986; 6: 935-40.
48. Hirai H, Sootome H, Nakatsuru Y et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010; 9: 1956-67.
49. Ashikawa K, Shishodia S, Fokt I, Priebe W, Aggarwal BB. Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem Pharmacol 2004; 67: 353-64.
50. Lima RT, Martins LM, Guimaraes JE, Sambade C, Vasconcelos MH. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 2004; 11: 309-16.
51. Fang J, Gu L, Zhu N, Tang H, Alvarado CS, Zhou M. Tissue factor/FVIIa activates Bcl-2 and prevents doxorubicin-induced apoptosis in neuroblastoma cells. BMC Cancer 2008; 8: 69.
52. Garcia MG, Alaniz L, Lopes EC, Blanco G, Hajos SE, Alvarez E. Inhibition of NF-kappaB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk Res 2005; 29: 1425-34.
53. Petrova Kruglova NS, Meschaninova MI, Venyaminova AG, Zenkova MA, Vlassov VV, Chernolovskaya EL. 2'-O-Methyl-modified anti-MDR1 Fork-siRNA duplexes exhibiting high nuclease resistance and prolonged silencing activity. Oligonucleotides 2010; 20: 297-308.
54. Laursen MB, Pakula MM, Gao S et al. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol Biosyst 2010; 6: 862-70.
55. Gaglione M, Messere A. Recent progress in chemically modified siRNAs. Mini Rev Med Chem 2010; 10: 578-95.
56. Bramsen JB, Pakula MM, Hansen TB et al. A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res 2010; 38: 5761-73.
57. Tamura A, Nagasaki Y. Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles. Nanomedicine (Lond) 2010; 5: 1089-102.
58. Higuchi Y, Kawakami S, Hashida M. Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs 2010; 24: 195-205.
59. Andersen MO, Howard KA, Kjems J. RNAi using a chitosan/siRNA nanoparticle system: in vitro and in vivo applications. Methods Mol Biol 2009; 555: 77-86.